This study aimed to conduct a comprehensive quantitative analysis of the available evidence from published RCT to assess the impact of sacubitril/valsartan vs. angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) on the life quality in patients with CHF. The gene discussed is ACE; the disease is congestive heart failure.